Improving drug delivery for pancreatic cancer treatment
Stromal targeting to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas
['FUNDING_R01'] · PURDUE UNIVERSITY · NIH-10981743
This study is looking at a new way to make treatments for pancreatic cancer work better by using a special method to deliver a helpful enzyme right into the tumor, which might help other medicines reach the cancer cells more easily, and it’s designed for patients who are facing this tough disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PURDUE UNIVERSITY (nih funded) |
| Locations | 1 site (WEST LAFAYETTE, UNITED STATES) |
| Trial ID | NIH-10981743 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of treatments for pancreatic ductal adenocarcinoma (PDAC) by targeting the dense stroma surrounding tumors. The approach involves developing a controlled release system for delivering hyaluronidase directly into the tumor, which may help break down barriers that prevent drugs from reaching cancer cells. By using advanced imaging techniques, the study aims to monitor how these therapies affect blood flow and drug distribution within the tumor. This could lead to more effective treatment options for patients suffering from this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the delivery and effectiveness of cancer treatments for patients with pancreatic ductal adenocarcinoma.
How similar studies have performed: Previous research has shown promise in using stromal targeting therapies for other cancers, indicating potential success for this novel approach in pancreatic cancer.
Where this research is happening
WEST LAFAYETTE, UNITED STATES
- PURDUE UNIVERSITY — WEST LAFAYETTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SOLORIO, LUIS — PURDUE UNIVERSITY
- Study coordinator: SOLORIO, LUIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancers